Six-week medicine switch for schizophrenia after first treatment failure
Treatments studied
Part of Mental health clinical trials.
This trial tests whether a more intensive medication approach for schizophrenia (or related conditions) helps people who didn’t improve on their first tried medicine. Participants will usually switch medicines and be compared against “treatment as usual.”
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 70 years old.
- You can give written consent (a legal guardian can help sign if allowed where you live).
- You are diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder.
- Your current episode didn’t respond to your current medicine (treatment failure) and you and your clinician plan to change the medicine.
- You have enough symptoms and daily-life problems to meet the study’s minimum thresholds.
- If you can get pregnant, you must use effective birth control and have a negative pregnancy test before randomization.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests a stronger medication approach after your first current treatment hasn’t worked well enough. It targets people with schizophrenia, major depressive disorder, or bipolar depression who still have significant symptoms and life impact.
This trial tests whether a stronger, more active medication plan for six weeks helps people with bipolar depression who did not improve with their first prescribed treatment. It compares the intensified medication plan to usual care to see which approach works better.
This study tests a more intensive antidepressant medicine approach for people whose first tried treatment didn’t work well enough. It compares the intensified treatment with usual care, aiming to improve depression symptoms and daily functioning.
This study tests two ways of switching from your current antipsychotic to a new combination medication (xanomeline and trospium). The goal is to see which approach is safer and easier for people with schizophrenia.
This study tests a new combination medication (xanomeline/trospium) for people with early schizophrenia who want to switch antipsychotics. The goal is to see if it helps control symptoms and is easier to tolerate.
This study follows people who were part of an earlier research trial about medication management during their first psychotic episode. Researchers want to understand how those early treatment choices affected their recovery over the past 20 years.
Hear when a new Schizophrenia and Related Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.